Cannara Biotech Reports Q2 2024 Financial Results
Net revenue, increased to $19.7 million in Q2 2024 from $13.0 million in Q2 2023, a 51.0% increase.
Gross profit, before fair value adjustments, increased to $7.1 million in Q2 2024 from $4.0 million in Q2 2023, a 77.2% increase.
Related news for (LOVFF)
- Cannara Biotech Delivers Record Q2 Results as National Expansion Accelerates
- Cannara Biotech Inc. to Announce Fiscal Q2 2025 Financial Results on April 28, 2025
- Cannara Biotech Announces Appointment of Justin Cohen to Board of Directors
- Cannara Biotech to Present at The Ventum Canadian Cannabis Conference on March 12th, 2025
- Cannara Biotech Reports Record Q1 2025 Revenue and National Market Share, Sets Stage for Continued Momentum in 2025